MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.65
-0.24
-1.21%
After Hours: 19.65 0 0.00% 16:50 02/21 EST
OPEN
19.85
PREV CLOSE
19.89
HIGH
20.14
LOW
19.62
VOLUME
653.20K
TURNOVER
--
52 WEEK HIGH
48.40
52 WEEK LOW
19.08
MARKET CAP
1.46B
P/E (TTM)
-55.3365
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MYGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MYGN stock price target is 21.86 with a high estimate of 36.00 and a low estimate of 14.00.

EPS

MYGN News

More
  • Myriad Genetics Shares Spike To Session High As Hearing Co. Wins Aetna Insurance Coverage For Its BRACAnalysis CDx Diagnostic
  • Benzinga · 5d ago
  • Edited Transcript of MYGN earnings conference call or presentation 6-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 6d ago
  • Steer Clear Of These 5 Toxic Stocks Before It's Too Late
  • Zacks · 6d ago
  • Myriad Genetics (MYGN) Releases Favorable Prolaris Results
  • Zacks · 6d ago

Industry

Medical Equipment, Supplies & Distribution
-0.81%
Healthcare Equipment & Supplies
-0.65%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About MYGN

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
More

Webull offers kinds of Myriad Genetics, Inc. stock information, including NASDAQ:MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions.